Anemia is a frequent and early chronic kidney disease (CKD) complication. Its management
is currently based on oral or intravenous iron supplements, erythropoiesis-stimulating …

Background Anaemia occurs in chronic kidney disease (CKD) and is more prevalent with
lower levels of kidney function. Anaemia in CKD is associated with death related to …

Roxadustat is a novel agent with a distinct mechanism of action compared to erythropoiesis-
stimulating agents (ESAs) and a potentially different combination of effects on iron …

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are oral
alternatives to current standard-of-care treatments for anaemia in chronic kidney disease …

Introduction This study was conducted to elucidate the safety of roxadustat, an oral
medication, in patients with non-dialysis-dependent (NDD) or incident dialysis dialysis …

Anemia is common in patients with chronic kidney disease (CKD) and is mainly caused by
insufficient production of erythropoietin from fibrotic kidney. Because anemia impairs quality …

Anemia is a common side effect of myelosuppressive chemotherapy; however,
chemotherapy‐induced anemia (CIA) management options are suboptimal. We evaluated …

Background: Anemia is a common and important complication in patients with chronic
kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis …

The discovery and development of erythropoiesis-stimulating agents was a journey lasting
more than a century, leading to the cloning and approval of recombinant human …

ABSTRACT Introduction Erythropoiesis-stimulating agents (ESAs) together with iron
supplementation had been the standard treatment for anemia in chronic kidney disease …